Delattre, O. et al. Gene fusion with an ETSDNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162–165 (1992).
Delattre, O. et al. The Ewing family of tumors—a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 331, 294–299 (1994).
Kovar, H. et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ. 7, 429–437 (1996).
Dohjima, T., Lee, N. S., Li, H., Ohno, T. & Rossi, J. J. Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol. Ther. 7, 811–816 (2003).
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E. & Triche, T. J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res. 65, 8984–8992 (2005).
Tanaka, K., Iwakuma, T., Harimaya, K., Sato, H. & Iwamoto, Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing’s sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 99, 239–247 (1997).
Boulay, G. et al. Cancer-specific retargeting of BAF complexes by a prion-like domain. Cell 171, 163–178 (2017).
Erkizan, H. V., Uversky, V. N. & Toretsky, J. A. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing’s sarcoma. Clin. Cancer Res. 16, 4077–4083 (2010).
Riggi, N. et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26, 668–681 (2014).
Tomazou, E. M. et al. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep. 10, 1082–1095 (2015).
Ahmed, N. S. et al. Fusion protein EWS-FLI1 is incorporated into a protein granule in cells. RNA 27, 920–932 (2021).
Gangwal, K. et al. Microsatellites as EWS/FLI response elements in Ewing’s sarcoma. Proc. Natl Acad. Sci. USA 105, 10149–10154 (2008).
Kim, S., Denny, C. T. & Wisdom, R. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol. Cell. Biol. 26, 2467–2478 (2006).
Bilke, S. et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res. 23, 1797–1809 (2013).
Stegmaier, K. et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 4, e122 (2007).
DuBois, S. G. et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr. Blood Cancer 52, 324–327 (2009).
Sankar, S. et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin. Cancer Res. 20, 4584–4597 (2014).
Erkizan, H. V. et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat. Med. 15, 750–756 (2009).
Grohar, P. J. et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 13, 145–153 (2011).
Grohar, P. J. et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J. Natl Cancer Inst. 103, 962–978 (2011).
Grohar, P. J. et al. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS−FLI1 fusion transcript. Cancer Chemother. Pharmacol. 80, 645–652 (2017).
Baruchel, S. et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children’s Oncology Group. Eur. J. Cancer 48, 579–585 (2012).
Reed, D. et al. Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma. J. Clin. Oncol. 39, 11514 (2021).
Felix, A. et al. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: actual knowledge and future directions to optimize the research. Cancer Med. 10, 1589–1604 (2021).
Larsen, A. K., Galmarini, C. M. & D’Incalci, M. Unique features of trabectedin mechanism of action. Cancer Chemother. Pharmacol. 77, 663–671 (2016).
Takebayashi, Y. et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 7, 961–966 (2001).
Pommier, Y. et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35, 13303–13309 (1996).
Zewail-Foote, M. et al. The inefficiency of incisions of ecteinascidin 743−DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem. Biol. 8, 1033–1049 (2001).
Aune, G. J. et al. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin. Cancer Res. 14, 6449–6455 (2008).
Soares, D. G. et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl Acad. Sci. USA 104, 13062–13067 (2007).
Germano, G. et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249–262 (2013).
Lau, L. et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children’s Oncology Group study. Clin. Cancer Res. 11, 672–677 (2005).
Scotlandi, K. et al. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin. Cancer Res. 8, 3893–3903 (2002).
Harlow, M. L. et al. Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Res. 76, 6657–6668 (2016).
Harlow, M. L. et al. Trabectedin inhibits EWS-FLI1 and evicts SWI/SNF from chromatin in a schedule-dependent manner. Clin. Cancer Res. 25, 3417–3429 (2019).
Grohar, P. J. et al. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin. Cancer Res. 20, 1190–1203 (2014).
Twelves, C. et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur. J. Cancer 39, 1842–1851 (2003).
Hancock, J. D. & Lessnick, S. L. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 7, 250–256 (2008).
Kinsey, M., Smith, R., Iyer, A. K., McCabe, E. R. & Lessnick, S. L. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing’s sarcoma. Cancer Res. 69, 9047–9055 (2009).
Richter, G. H. et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc. Natl Acad. Sci. USA 106, 5324–5329 (2009).
Zhang, H. F. et al. Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma. Cancer Discov. 11, 2884–2903 (2021).
Camoes, M. J. et al. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing’s sarcoma and prostate carcinoma. PLoS ONE 7, e49819 (2012).
Orth, M. F. et al. Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. Cell Rep. 41, 111761 (2022).
Bading, J. R. & Shields, A. F. Imaging of cell proliferation: status and prospects. J. Nucl. Med. 49, 64S–80S (2008).
Osgood, C. L. et al. 18F-FLT positron emission tomography (PET) is a pharmacodynamic marker for EWS-FLI1 activity and Ewing sarcoma. Sci. Rep. 6, 33926 (2016).
Perez-Ruixo, J. J. et al. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin. Pharmacokinet. 46, 867–884 (2007).
Poggesi, I. et al. Population pharmacokinetics of trabectedin in adolescent patients with cancer. Cancer Chemother. Pharmacol. 84, 707–717 (2019).
van Kesteren, C. et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 13, 381–393 (2002).
Attia, S. et al. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med. 12, 1532–1539 (2023).
Italiano, A. et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 21, 446–455 (2020).
Collier, A. B. et al. Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: a report from the Children’s Oncology Group. Pediatr. Blood Cancer 68, e29333 (2021).
Duffaud, F. et al. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. Br. J. Cancer 129, 1940–1948 (2023).
Demetri, G. D. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J. Clin. Oncol. 27, 4188–4196 (2009).
Osgood, C. L. et al. Identification of mithramycin analogues with improved targeting of the EWS-FLI1 transcription factor. Clin. Cancer Res. 22, 4105–4118 (2016).
Shulman, D. S. et al. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 12, 15207–15216 (2023).
